Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G4A | P47712 | 18/20 | 1.00 |
| ▸ | PLA2G6 | O60733 | 1/20 | 1.00 |
| ▸ | PLA2G4C | Q9UP65 | 2/20 | 0.74 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22222834 | 1.00 | PLA2G4A (1.00) | PLA2G4APLA2G6PLA2G4CPTPN1 | |
| SCHEMBL22187659 | 1.00 | PLA2G4A (1.00) | PLA2G4APLA2G6PLA2G4CPTPN1 | |
| SCHEMBL22222879 | 1.00 | PLA2G4A (1.00) | PLA2G4APLA2G6PLA2G4CPTPN1 | |
| SCHEMBL2729842 | 1.00 | PLA2G4A (1.00) | PLA2G4APLA2G6PLA2G4CPTPN1 | |
| SCHEMBL22222880 | 1.00 | PLA2G4A (1.00) | PLA2G4APLA2G6PLA2G4CPTPN1 | |
| SCHEMBL3686137 | 1.00 | PLA2G4A (1.00) | PLA2G4APLA2G6PLA2G4CPTPN1 | |
| SCHEMBL22222825 | 0.78 | PLA2G4A (1.00) | PLA2G4APLA2G6PLA2G4C | |
| SCHEMBL3686144 | 0.77 | PLA2G4A (0.62) | PLA2G4APLA2G6PLA2G4CPTPN1 | |
| SCHEMBL30007459 | 0.73 | PLA2G4A (1.00) | PLA2G4APLA2G6PLA2G4C | |
| SCHEMBL22222831 | 0.70 | PLA2G4A (0.54) | PLA2G4APLA2G6PLA2G4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4243805-A1 | COMBINATION THERAPIES FOR TREATING CORONAVIRUS INFECTION | Gbiotech S.À.R.L. (CH) | 2023-09-20 | — | — | EP | claimed |
| WO-2022239725-A1 | AGRICULTURAL AND HORTICULTURAL FUNGICIDAL COMPOSITION | 日本曹達株式会社 | 2022-11-17 | — | — | WO | claimed |
| WO-2022230804-A1 | AGRICULTURAL AND HORTICULTURAL FUNGICIDAL COMPOSITION | 日本曹達株式会社 | 2022-11-03 | — | — | WO | claimed |
| WO-2022029334-A1 | COMBINATION THERAPIES FOR TREATING CORONAVIRUS INFECTION | GBIOTECH S.À.R.L. (CH) | 2022-02-10 | — | — | WO | claimed |
| US-12590309-B2 | Reprogramming of lipid metabolism to inhibit T cell senescence and enhance tumor immunotherapy | SAINT LOUIS UNIVERSITY (US) | 2026-03-31 | — | — | US | disclosed |
| EP-3509604-B1 | COMBINATION THERAPIES USING IMMUNO-DASH INHIBITORS AND PGE2 ANTAGONISTS | TUFTS COLLEGE (US) | 2026-02-18 | — | — | EP | disclosed |
| US-12478609-B2 | Combination therapies using immuno-DASH inhibitors and PGE2 antagonists | TRUSTEES OF TUFTS COLLEGE (US) | 2025-11-25 | — | — | US | disclosed |
| WO-2025126830-A1 | N-SUBSTITUTED OXY-2-AMINOTHIAZOLECARBOXAMIDE COMPOUND OR SALT THEREOF AND AGRICULTURAL AND HORTICULTURAL BACTERICIDE | 石原産業株式会社 | 2025-06-19 | — | — | WO | disclosed |
| WO-2025121401-A1 | PYRAZOLE COMPOUND AND HARMFUL ORGANISM CONTROL AGENT | 日産化学株式会社 | 2025-06-12 | — | — | WO | disclosed |
| WO-2025110227-A1 | PYRAZOLE COMPOUND AND HARMFUL ORGANISM CONTROL AGENT | 日産化学株式会社 | 2025-05-30 | — | — | WO | disclosed |
| WO-2025110202-A1 | AGENT FOR IMPROVING PLANT NON-BIOLOGICAL STRESS RESISTANCE, METHOD FOR IMPROVING NON-BIOLOGICAL STRESS RESISTANCE, PREPARATION FOR IMPROVING NON-BIOLOGICAL STRESS RESISTANCE, PRODUCT FOR IMPROVING NON-BIOLOGICAL STRESS RESISTANCE, AND PLANT | 株式会社クレハ | 2025-05-30 | — | — | WO | disclosed |
| WO-2025110205-A1 | AGENT FOR IMPROVING DAMAGE-RECOVERING PROPERTIES OF PLANT, PREPARATION FOR IMPROVING DAMAGE-RECOVERING PROPERTIES, METHOD FOR IMPROVING DAMAGE-RECOVERING PROPERTIES OF PLANT, PLANT BODY, AND AGENT FOR IMPROVING PHYSICAL STRESS RESISTANCE OF PLANT | 株式会社クレハ | 2025-05-30 | — | — | WO | disclosed |
| US-20220220482-A1 | REPROGRAMMING OF LIPID METABOLISM TO INHIBIT T CELL SENESCENCE AND ENHANCE TUMOR IMMUNOTHERAPY | SAINT LOUIS UNIVERSITY (US) | 2022-07-14 | — | — | US | disclosed |
| CN-114467949-A | Synergistic composition containing quinolone compounds and application thereof | 山东省联合农药工业有限公司 | 2022-05-13 | — | — | CN | disclosed |
| WO-2022092084-A1 | FUSED HETEROCYCLE DERIVATIVE AND HERBICIDE CONTAINING SAME AS ACTIVE INGREDIENT | クミアイ化学工業株式会社 | 2022-05-05 | — | — | WO | disclosed |
| WO-2022065235-A1 | IMIDAZO[1,2-A]PYRIDINE COMPOUND AND PEST CONTROL AGENT | 日本曹達株式会社 | 2022-03-31 | — | — | WO | disclosed |
| US-20220040149-A1 | COMBINATION THERAPIES USING IMMUNO-DASH INHIBITORS AND PGE2 ANTAGONISTS | TRUSTEES OF TUFTS COLLEGE | 2022-02-10 | — | — | US | disclosed |
| WO-2022029334-A1 | COMBINATION THERAPIES FOR TREATING CORONAVIRUS INFECTION | GBIOTECH S.À.R.L. (CH) | 2022-02-10 | — | — | WO | disclosed |
| WO-2022032082-A1 | BIOINSECTICIDE | KANNAR EARTH SCIENCE, LTD. (US) | 2022-02-10 | — | — | WO | disclosed |
| WO-2022024486-A1 | HERBICIDE COMPOSITION AND WEED CONTROLLING METHOD | 住友化学株式会社 | 2022-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12478609-B2 | Combination therapies using immuno-DASH inhibitors and PGE2 antagonists | HPGDS, PTGIS, PTGDR2 | PLA2G4A 25/4885PLA2G6 165/4885PLA2G4C 36/4885 |
| US-12590309-B2 | Reprogramming of lipid metabolism to inhibit T cell senescence and enhance tumor immunotherapy | PLA2G4A, PLA2G2A, PLA2G1B | PLA2G4A 1/4885PLA2G6 14/4885PLA2G4C 9/4885 |
| US-20220040149-A1 | COMBINATION THERAPIES USING IMMUNO-DASH INHIBITORS AND PGE2 ANTAGONISTS | HPGDS, PTGIS, PTGDR2 | PLA2G4A 25/4885PLA2G6 165/4885PLA2G4C 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.